Imatinib is a first generation TKI approved for the treatment of CML and Philadelphia-positive acute lymphoblastic leukemia (ALL) and for myelodysplastic/myeloproliferative diseases carrying the PDGFR rearrangement. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.